Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy -Cohort study using claim database-

Next Previous
X
Search
Trial Profile

Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy -Cohort study using claim database-

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical

    • Most Recent Events

    • 29 Jul 2022 Primary endpoint (Duration of treatment persistence with the BRX and OAA groups in patients with schizophrenia) has been met, as per results pulished in the Advances in Therap.
    • 29 Jul 2022 Results of retrospective analysis comparing the time to treatment discontinuation between patients with schizophrenia prescribed brexpiprazole group and those prescribed other atypical antipsychotics group in clinical settings, pulished in the Advances in Therap.
    • 10 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top